--- title: "4D Molecular Therapeutics (FDMT) news: offering" url: "https://aibio.space/companies/4d-molecular-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "FDMT offering news: 4D Molecular Therapeutics prices $99,999,993 stock offering at $10.5100. 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT), United States." --- FDMT 4D Molecular Therapeutics, Inc. NASDAQ · United States # 4D Molecular Therapeutics (FDMT) news FDMT offering news Debt Financing · 2026-06-24 ## [4D Molecular Therapeutics signs up to $200.0 million Hercules loan](https://aibio.space/news/4d-molecular-therapeutics-signs-up-200-0-million-hercules-loan/) Hercules Capital, Inc. is the lender on senior secured term loans that mature in 2031, and most of the money is milestone-based or at the lender's discretion. The filing does not say how the company will use the proceeds. ## Latest 4D Molecular Therapeutics news 1. 2026-01-26 Financings [4D Molecular swaps common stock for pre-funded warrants with RA Capital and BVF](https://aibio.space/news/4d-molecular-swaps-common-stock-pre-funded-warrants-ra-capital-bvf/) RA Capital exchanged 4,850,000 shares and Biotechnology Value Fund exchanged 1,750,000 shares. The company had 51,007,874 shares outstanding as of January 23, 2026. 2. 2025-11-06 Financings [4D Molecular Therapeutics prices $99,999,993 stock offering at $10.5100](https://aibio.space/news/4d-molecular-therapeutics-prices-99-999-993-stock-offering-10-5100/) 4D Molecular Therapeutics priced an offering of about $100 million in shares and pre-funded warrants at $10.51 each, with Leerink Partners LLC and Evercore Group L.L.C. as joint bookrunners. Preliminary cash of $372.2 million is unaudited, and new buyers face immediate dilution of $1.36 per share. 3. 2025-10-31 Financings [4D Molecular Therapeutics licenses 4D-150 to Otsuka in Asia-Pacific deal with $85 million upfront](https://aibio.space/news/4d-molecular-therapeutics-licenses-4d-150-otsuka-asia-pacific-deal-85/) 4D Molecular Therapeutics agreed on October 31, 2025 to license 4D-150 to Otsuka for Asia-Pacific markets in exchange for an $85 million upfront payment. The company keeps leading global Phase 3 work, and Otsuka's expected cost sharing is at least $50 million over three years. ## 4D Molecular Therapeutics at a glance - **Ticker**: FDMT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $361.3 million ### Related companies - [NeOnc Technologies Holdings](https://aibio.space/companies/neonc-technologies/) NASDAQ: NTHI - [MindWalk Holdings](https://aibio.space/companies/mindwalk/) NASDAQ: HYFT - [Attovia Therapeutics](https://aibio.space/companies/attovia-therapeutics/) NASDAQ: ATTO - [PepGen](https://aibio.space/companies/pepgen/) NASDAQ: PEPG - [Arvinas](https://aibio.space/companies/arvinas/) NASDAQ: ARVN - [SORRENTO THERAPEUTICS INC](https://aibio.space/companies/sorrento-therapeutics/) OTC: SRNE - [Manhattan Scientifics](https://aibio.space/companies/manhattan-scientifics/) OTC: MHTX - [ANI Pharmaceuticals](https://aibio.space/companies/ani-pharmaceuticals/) NASDAQ: ANIP ### Also on NASDAQ - [TELA Bio](https://aibio.space/companies/tela-bio/) TELA - [Aardvark Therapeutics](https://aibio.space/companies/aardvark-therapeutics/) AARD - [BioAge Labs](https://aibio.space/companies/bioage-labs/) BIOA - [AtriCure](https://aibio.space/companies/atricure/) ATRC - [IceCure Medical](https://aibio.space/companies/icecure-medical/) ICCM - [Pyxis Oncology](https://aibio.space/companies/pyxis-oncology/) PYXS ## 4D Molecular Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$85.2 million](https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/) | [$37,000](https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/) | | Research and development | [$195.7 million](https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/) | [$141.3 million](https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/) | | Net income (loss) | [-$140.1 million](https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/) | [-$160.9 million](https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/) | | Cash from operations | [-$109.1 million](https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/) | [-$134.6 million](https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/) | | Cash and equivalents | [$60.2 million](https://www.sec.gov/Archives/edgar/data/1650648/000119312526349173/) | [$149.3 million](https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/) | | Short-term investments | [$342.4 million](https://www.sec.gov/Archives/edgar/data/1650648/000119312526349173/) | [$275.5 million](https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $70.4 million, plus short-term investments of $291.0 million, $361.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about 4D Molecular Therapeutics Has 4D Molecular Therapeutics raised money recently? Our latest story on this, dated Nov 6, 2025: "4D Molecular Therapeutics prices $99,999,993 stock offering at $10.5100". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/4d-molecular-therapeutics-prices-99-999-993-stock-offering-10-5100/). What is the ticker symbol of 4D Molecular Therapeutics? 4D Molecular Therapeutics, Inc. trades under the ticker FDMT on NASDAQ. Where is 4D Molecular Therapeutics listed? 4D Molecular Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of 4D Molecular Therapeutics? The SEC Central Index Key (CIK) for 4D Molecular Therapeutics, Inc. is 1650648. Its filings are on SEC EDGAR. How many shares does 4D Molecular Therapeutics have outstanding? 49,778,127 shares as of 2024-02-23, per the cover page of its 10-K filed 2024-02-29. Which country or territory is 4D Molecular Therapeutics listed under? Our directory records 4D Molecular Therapeutics, Inc. under United States. What does 4D Molecular Therapeutics do? Our directory classifies 4D Molecular Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of 4D Molecular Therapeutics? The ISIN recorded for 4D Molecular Therapeutics, Inc. is US35104E1001. Does aibio.space cover 4D Molecular Therapeutics? aibio.space lists 4D Molecular Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is 4D Molecular Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What was 4D Molecular Therapeutics's revenue last year? $85.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is 4D Molecular Therapeutics profitable? 4D Molecular Therapeutics, Inc. reported a net loss of $140.1 million for the fiscal year ended Dec 31, 2025, and used $109.1 million of cash in operations, per its annual report to the SEC. How much does 4D Molecular Therapeutics spend on research and development? $195.7 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does 4D Molecular Therapeutics have? $361.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest 4D Molecular Therapeutics (FDMT) stock news? Our latest story on 4D Molecular Therapeutics, dated Jun 24, 2026: "4D Molecular Therapeutics signs up to $200.0 million Hercules loan". Hercules Capital, Inc. is the lender on senior secured term loans that mature in 2031, and most of the money is milestone-based or at the lender's discretion. The filing does not say how the company will use the proceeds. [Source](https://aibio.space/news/4d-molecular-therapeutics-signs-up-200-0-million-hercules-loan/). ## Investor discussion: 4D Molecular Therapeutics Members talk about 4D Molecular Therapeutics (FDMT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at 4D Molecular Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-01-26 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1650648/000119312526022559/fdmt-20260122.htm) 2. 2025-11-06 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1650648/000119312525269700/d52514d424b5.htm) 3. 2024-12-11 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1650648/000095017024135381/fdmt-20241206.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:FDMT on TradingView](https://www.tradingview.com/symbols/NASDAQ-FDMT/). ## SEC filings and registration - **SEC name**: 4D Molecular Therapeutics, Inc. - **CIK**: 1650648 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: FDMT (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 5858 HORTON STREET #455, EMERYVILLE, CA, 94608 - **Phone**: 5105052680 - **Shares outstanding**: 49,778,127 as of 2024-02-23 (10-K filed 2024-02-29) - **Former names**: 4D Molecular Therapeutics Inc.; 4D Molecular Therapeutics Inc ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1650648/000119312526403424/d147828d8k.htm) filed 2026-09-28 - [10-Q](https://www.sec.gov/Archives/edgar/data/1650648/000119312526349173/fdmt-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-20260813.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1650648/000119312526308409/d98747d8k.htm) filed 2026-07-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1650648/000119312526286880/d146057d8k.htm) filed 2026-06-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1650648/000119312526277563/fdmt-20260617.htm) filed 2026-06-22 - [S-3](https://www.sec.gov/Archives/edgar/data/1650648/000119312526212323/d298087ds3.htm) filed 2026-05-07 - [10-Q](https://www.sec.gov/Archives/edgar/data/1650648/000119312526211939/fdmt-20260331.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001650648), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details 4D Molecular Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker FDMT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: 4D Molecular Therapeutics, Inc. - **Ticker**: FDMT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US35104E1001 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-FDMT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/4d-molecular-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "4D Molecular Therapeutics (FDMT) news: offering", 2026-10-31, https://aibio.space/companies/4d-molecular-therapeutics/